Prostate-protective action of combined composition suppositories with indole-3-carbinol and meloxicam on model of sulpiride-induced benign prosate hyperplasia

Authors

  • Zaychenko G. Bogomolets National Medical University, Kyiv
  • Ravshanov T. National university of pharmacy, Kharkiv

DOI:

https://doi.org/10.21856/j-PEP.2019.1.12

Keywords:

benign hyperplasia, prostate, rectal suppositories, indole-3-carbinol, 5α-reductase

Abstract

Benign prostatic hyperplasia in rats after chronic administration of sulpiride was corrected by administration (rectal suppositories) containing indole-3-carbinol and meloxicam. Established that suppositories correct the mass coefficients of the sex glands, the degree of androgenization of the organism of male rats, positively effect on concentration of fructose in seminal vesicles, activity of phosphatases and function of urinary system. Suppositories do not have a gonadotoxic effect, contribute to normalization of the hormonal function of testes with improving of spermatogenesis. A significant decrease of pathological changes in the gland at cellular level revealed: normalization of 5α-reductase activity, concentration of sex hormone receptors, as result of the specific activity of active ingredient of suppositories - indol-3-carbinol. The expressive prostate-protective action of the combined composition suppositories exceeds such a reference preparation – suppositories with pumpkin seed oil.

References

Mobley D, Feibus A, Baum N. Postgrad Med 2015;127 (3): 301-307. doi: http://doi.org/10.1080/00325481.2015.1018799.

Pelletier G, et al. J Mol Endocrinol 2001; 26 (1): 11-19.

Habib FK, et al. J Endocrinol 1998; 156 (3): 509-517.

Medina JJ, Parra RO, Moore RG. Med Clin North Am 1999; 83 (5): 1213-1229.

Pechersky AV, Semiglazov VF, Mazurov VI, et al. Int J Androl 2002; 25: 119-125.

Tjuzikov IA, Martov AG, Grekov EA. Jeksperim Klin Urologija 2012; 3: 39-47.

Oelke M. et al. Maturitas 2012;71(1): 8-12.

Caine M, Pfau A, Perlberg S. Brit J Urol 1976; 48 (3): 255-263. doi: https://doi.org/10.1111/j.1464-410X.1976.tb10214.x

Nickel JC. Rev Urol 2004;6(9): S31.

Oelke M, et al. Eur Urol 2012; 61 (5): 917-925. doi:http://doi.org/10.1016/j.eururo.2012.01.013.

Tyagi P, Tyagi V, Chancellor M. Exp Opin Drug Saf 2011;10 (2): 287-294. doi: http://doi.org/10.1517/14740338.2011.542146.

McVary KT, et al. J Urol 2011; 185 (5): 1793-1803. doi:http://doi.org/10.1016/j.juro.2011.01.074.

Gorpinchenko II et al. Zdorov'e Muzhchiny 2013; 3: 16-24.

Verhoeven DTH, et al. Chemico-biological interactions 1997; 103 (2): 79-129.

Hsu JC, et al. Carcinogenesis 2005; 26 (11): 1896-1904.

Teodorovich OV, et al. Jeffektivnaja Farmakoterapija 2016; 33: 10-16.

Korneev IA. Urologija 2017; 3: 138-144.

Vyshnevs'kyj EM. Strasburg, 18 bereznja 1986 roku: Zb. dogovoriv Rady Evropy: Ukrai'ns'ka versija, 2000.

Lapach SN, Gubenko AV, Babich PN. Statisticheskie metody v mediko-biologicheskih issledovanijah s ispol'zovaniem Excel, Kiev, 2001: 408 p.

Van Coppenolle F, et al. Am J Physiol Endocrinol Metab 2001; 280 (1): E120-E129.

Kalinchenko SJu. Shag vpered v lechenii giperprolaktinemii, Moskva, 2010: 96 p.

Kalinchenko SJu, Tjuzikov IA. Prakticheskaja andrologija,Moskva, 2009: 400 p.

Downloads

Published

2021-07-06

How to Cite

Zaychenko, G. ., & Ravshanov, T. . (2021). Prostate-protective action of combined composition suppositories with indole-3-carbinol and meloxicam on model of sulpiride-induced benign prosate hyperplasia. Problems of Endocrine Pathology, 67(1), 95-103. https://doi.org/10.21856/j-PEP.2019.1.12